advanced search
SUSTAINED DRUG DELIVERY TO THE POSTERIOR SEGMENTS OF THE EYE
OCULAR
Dr Shikha P Barman
SUSTAINED DRUG DELIVERY TO THE POSTERIOR SEGMENTS OF THE EYE
Shikha Barman reviews approaches for delivering drugs for diseases of the back of the eye, and introduces EySite-InjecT™.
AQUEOUS-FREE OPHTHALMIC DELIVERY TECHNOLOGY
OCULAR
Dr Christian Roesky
AQUEOUS-FREE OPHTHALMIC DELIVERY TECHNOLOGY
Traditional aqueous vehicles for topical ophthalmic medications suffer from a number of limitations. Christian Roesky reviews the benefits of EyeSol®, a proprietary aqueous-free drug delivery technology.
FANNY SELLIER, NEMERA
INTERVIEW
Fanny Sellier
Nemera
FANNY SELLIER, NEMERA
Talking here with ONDrugDelivery Magazine, Ms Sellier discusses Nemera’s multidose eyedropper system Novelia® for preservative-free formulations. She explains how this platform has been developed to improve patients’ lives.
PHYSICOCHEMICAL BIOEQUIVALENCE IN OPHTHALMIC MICROEMULSIONS
EXPERT VIEW
Dr Paul Kippax
PHYSICOCHEMICAL BIOEQUIVALENCE IN OPHTHALMIC MICROEMULSIONS
Here, Paul Kippax describes the methods by which bioequivalence can be established for ophthalmic microemulsions by in vitro testing, saving the need for costly clinical trials.
USING PHYSICAL FORCES TO ENHANCE OCULAR DRUG DELIVERY
EXPERT VIEW
Di Huang
USING PHYSICAL FORCES TO ENHANCE OCULAR DRUG DELIVERY
Di Huang, Erica Chen and Ilva Rupenthal discuss the possibilities offered by physical force-based methods of enhancing the efficacy of ophthalmic drug delivery by providing a way past the eye’s natural barriers.
SUSTAINED RELEASE OCULAR THERAPEUTICS
EXPERT VIEW
Michael O'Rourke
SUSTAINED RELEASE OCULAR THERAPEUTICS
Michael O’Rourke gives an overview of the current state of the ophthalmics market, going into greater detail on the opportunities offered in the area of sustained-release technologies and therapies.
BIODEGRADABLE IMPLANTS FOR SUSTAINED INTRAOCULAR DELIVERY
OCULAR
Dr Raj Thakur
BIODEGRADABLE IMPLANTS FOR SUSTAINED INTRAOCULAR DELIVERY
Raj Thakur and Prof David Jones discuss the difficulty of treating diseases of the back and front of the eye, and introduce a possible solution: OcuLief™ and EyeLief™, Re-Vana’s two proprietary sustained-release platforms.
CREATING SUSTAINABLE BIOTHERAPEUTICS FACTORIES IN THE EYE
OCULAR
Dr Patricia Zilliox
CREATING SUSTAINABLE BIOTHERAPEUTICS FACTORIES IN THE EYE
Patricia Zilliox discusses the inherent difficulties in drug delivery to the back of the eye and how this creates an unmet need in ophthalmology. Dr Zilliox goes on to describe Eyevensys’ novel solution to this problem, and the company’s first lead product, EYS606.
CONNECTED HEALTH – AN EFFECTIVE SOLUTION TO IMPROVE ADHERENCE
CONNECTIVITY
Sai Shankar
Aptar Pharma
CONNECTED HEALTH – AN EFFECTIVE SOLUTION TO IMPROVE ADHERENCE
Sai Shankar details the problem of non-adherence, in particular in asthma and COPD, and how its solution, along with myriad other benefits, can be found in digital healthcare and connected devices.
NEIL WILLIAMS, MEDICOM INNOVATION PARTNER
INTERVIEW
Neil Williams
NEIL WILLIAMS, MEDICOM INNOVATION PARTNER
In this interview with ONdrugDelivery Magazine, Williams discusses the crucial role connectivity is taking in the drug delivery device industry.
IMPROVING PATIENTS’ LIVES THROUGH CONNECTIVITY
CONNECTIVITY
Matthieu Hamon
Biocorp
IMPROVING PATIENTS’ LIVES THROUGH CONNECTIVITY
Eric Dessertenne and Matthieu Hamon look at the importance of increasing the connectivity of drug delivery devices to improve patient compliance in the area of chronic disease management. Biocorp aims to use innovations such as Datapen™ and EasyLog™ to help create patient-centric, interconnected care, known as 4P medicine.
SOFTWARE AND SERVICES – THE MISSING LINK FOR CONNECTED THERAPEUTICS
CONNECTIVITY
Alexander Dahmani
SOFTWARE AND SERVICES – THE MISSING LINK FOR CONNECTED THERAPEUTICS
Alexander Dahmani explains how the rise of smart devices and connectivity has enabled QuiO to develop ConnectedRx™, the first cloud platform designed for connected therapeutics, and discusses how ConnectedRx™ programmes can be a step towards solving the ongoing problem of adherence.
HOW CONNECTIVITY WILL REMODEL HEALTHCARE
EXPERT VIEW
Dr Marjorie Villien
HOW CONNECTIVITY WILL REMODEL HEALTHCARE
Marjorie Villien and Jerôme Mouly provide a forecast of the place of connectivity in the healthcare market and the significant changes it is likely to bring to both devices and the market itself.
THE PROMISE OF VOICE: CONNECTING DRUG DELIVERY THROUGH VOICE-ACTIVATED TECHNOLOGY
EXPERT VIEW
Chris Franzese
THE PROMISE OF VOICE: CONNECTING DRUG DELIVERY THROUGH VOICE-ACTIVATED TECHNOLOGY
Chris Franzese and Marty Coyne discuss the vast potential that voice-activated technologies, such as Amazon’s Alexa, have in the healthcare market. Running through the challenges posed by data security and human factors, they go on to explain how the rewards voice-activation offers are well worth the effort, spanning the drug delivery experience.
CONNECTIVITY IN DRUG DELIVERY
CONFERENCE REVIEW
Napoleon Monroe
CONNECTIVITY IN DRUG DELIVERY
Napoleon Monroe summarises the intensifying coverage of connectivity as a key theme at two recent drug delivery conferences he attended, Partnerships in Drug Delivery and PDA’s Universe of Prefilled Syringes and Injection Devices.
PARTNERING FOR BLUETOOTH: THE SMART ROAD TO CONNECTIVITY
CONNECTIVITY
Thomas Soederholm
PARTNERING FOR BLUETOOTH: THE SMART ROAD TO CONNECTIVITY
Thomas Soederholm explains how advances in wireless technology, such as new Bluetooth Low Energy chips and design tools, are now being used in wireless medical product development and how incorporating them can be made much easier by partnering with a specialist vendor.
ENERGY HARVESTING: POWERING CONNECTED DRUG DELIVERY DEVICES
EXPERT VIEW
Charlotte Harvey
ENERGY HARVESTING: POWERING CONNECTED DRUG DELIVERY DEVICES
Charlotte Harvey examines the opportunities and practicalities of using energy harvesting technologies in drug delivery devices. With a specific focus on enabling connectivity functionality, Ms Harvey runs through the various aspects of energy harvesting and offers insight on whether it is the right choice for a new device development.
DATA IS DRIVING THE FUTURE OF NEUROTECHNOLOGY WITH CRANIALCLOUD
CONNECTIVITY
Will Rosellini
DATA IS DRIVING THE FUTURE OF NEUROTECHNOLOGY WITH CRANIALCLOUD
Will Rosellini, Nexeon Medsystems, and Pierre-Francois D’Haese, Neurotargeting, discuss the neurotechnology market and how the Internet of Medical Things is creating exciting opportunities in the space. looking specifically at the collaboration centring Nexeon’s Deep Brain Stiumulation technology and Neurotargeting’s CrainialCloud.
THE SCIENCE BEHIND CAPSULE-BASED DRY POWDER INHALATION TECHNOLOGY
PULMONARY
Fernando Díez
ACG
THE SCIENCE BEHIND CAPSULE-BASED DRY POWDER INHALATION TECHNOLOGY
Here, Fernando Díez, Justin Kalafat, and Jnanadeva Bhat explain the mechanics behind cDPIs, from the scientific perspective, before looking to the future of cDPIs in the market.
THE LATEST DIGITAL TOOLS REVEAL ACTUAL PATIENT BEHAVIOUR
EXPERT VIEW
Ryan Noble
THE LATEST DIGITAL TOOLS REVEAL ACTUAL PATIENT BEHAVIOUR
Ryan Noble and Tom Lawrie-Fussey discuss the potential of digital innovations to improve understanding of real patient behaviour and consequently increase adherence.
ADDRESSING THE CHALLENGES IN NASAL DEVICE TESTING: EVALUATION OF PUMP PERFORMANCE
NASAL
Heli Chauhan
Proveris Scientific
ADDRESSING THE CHALLENGES IN NASAL DEVICE TESTING: EVALUATION OF PUMP PERFORMANCE
Heli Chauhan details the myriad challenges facing the OINDP market, with a particular emphasis on nasal spray devices, when it comes to testing products on a mass-production scale, such as a lack of adequate testing equipment and the need to capture accurate data consistently. She goes on to offer a solution in the form of Indizo®, Proveris’ automated nasal spray testing apparatus.
A SIMPLE AFFORDABLE DPI: MEETING THE NEEDS OF EMERGING MARKETS
PULMONARY
Dr Anselm Ebert
H&T Presspart
A SIMPLE AFFORDABLE DPI: MEETING THE NEEDS OF EMERGING MARKETS
Anselm Ebert, João Ventura Fernandes, Ameet Sule and Sunita Sule discuss the rising need for respiratory medication in the developing world. They go on to highlight the novel challenges presented by these new markets and explain how a new DPI, PowdAir Plus™, meets those challenges, offering a solution to the increase in chronic respiratory conditions across the globe.
AN OVERVIEW OF DRY POWDER INHALATION FOR SYSTEMIC DRUG DELIVERY
PULMONARY
Brian E Jones
Qualicaps
AN OVERVIEW OF DRY POWDER INHALATION FOR SYSTEMIC DRUG DELIVERY
Brian Jones and Susana Ecenarro Probst discuss the growing interest in using inhaled APIs to treat systemic conditions. Furthermore, they review some of the methods used to engineer molecules to be suitable for DPI capsules and look to the possibility of administering biomolecules via the pulmonary route.
THE DEVELOPMENT PATH TO BIOEQUIVALENCE FOR A NASAL SPRAY
NASAL
Pascale Farjas
Nemera
THE DEVELOPMENT PATH TO BIOEQUIVALENCE FOR A NASAL SPRAY
Pascale Farjas, Alain Regard, and Céline Petitcolas discuss the steps taken when designing a nasal spray device for the growing bioequivalence market and the key competencies, including experience with regulations and regulatory agencies in numerous geographic regions, that Nemera can offer throughout the process.

See what ondrugdelivery's readers and contributors think


Matt Kempton user photo
Matt Kempton
Snr Project Engineer
Corning Incorporated

I am extremely impressed with the comprehensive presentation of information and problem/solution points detailed ... Kudos to you for an extremely well written article with succinct and robust scientific body of knowledge.


Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.


Abby Lockwood Opus Strategy photo
Abby Lockwood
Consultant
Plan Strategic

ONdrugDelivery Magazine is a great resource that brings a lot of value to the work my team and I are doing in the area of drug delivery. The device-specific content as well as the broader discussions surrounding industry trends and issues are extremely informative and very well written.


Dr Cristian Vilos

I‘m working on the development of microparticles for the release of veterinary antibiotics, and polymeric nanoparticles for siRNA and chemotherapeutic delivery. ONdrugDelivery has been a very usefull platform to connect the scientific research, and marketed drug development.


Top